Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment : study protocol for a phase II, multicentre, non-randomised study
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Multidrug chemoimmunotherapy with rituximab, high-dose methotrexate, procarbazine and vincristine (R-MPV) is a standard therapy for younger patients with primary central nervous system lymphoma (PCNSL); however, prospective data regarding its use in elderly patients are lacking. This multi-institutional, non-randomised, phase II trial will assess the efficacy and safety of R-MPV and high-dose cytarabine (HD-AraC) for geriatric patients with newly diagnosed PCNSL.
METHODS AND ANALYSIS: Forty-five elderly patients will be included. If R-MPV does not achieve complete response, the patients will undergo reduced-dose, whole-brain radiotherapy comprising 23.4 Gy/13 fractions, followed by local boost radiotherapy comprising 21.6 Gy/12 fractions. After achieving complete response using R-MPV with or without radiotherapy, the patients will undergo two courses of HD-AraC. All patients will undergo baseline geriatric 8 (G8) assessment before HD-AraC and after three, five and seven R-MPV courses. Patients with screening scores of ≥14 points that decrease to <14 points during subsequent treatment, or those with screening scores <14 points that decrease from the baseline during subsequent treatment are considered unfit for R-MPV/HD-AraC. The primary endpoint is overall survival, and the secondary endpoints are progression-free survival, treatment failure-free survival and frequency of adverse events. The results will guide a later phase III trial and provide information about the utility of a geriatric assessment for defining chemotherapy ineligibility.
ETHICS AND DISSEMINATION: This study complies with the latest Declaration of Helsinki. Written informed consent will be obtained. All participants can quit the study without penalty or impact on treatment. The protocol for the study, statistical analysis plan and informed consent form have been approved by the Certified Review Board at Hiroshima University (CRB6180006) (approval number: CRB2018-0011). The study is ongoing within nine tertiary and two secondary hospitals in Japan. The findings of this trial will be disseminated through national and international presentations and peer-reviewed publications.
TRIAL REGISTRATION: jRCTs061180093.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
BMJ open - 13(2023), 4 vom: 24. Apr., Seite e071350 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamasaki, Fumiyuki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.04.2023 Date Revised 04.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2022-071350 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355985799 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355985799 | ||
| 003 | DE-627 | ||
| 005 | 20231226210302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2022-071350 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355985799 | ||
| 035 | |a (NLM)37094899 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamasaki, Fumiyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment |b study protocol for a phase II, multicentre, non-randomised study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2023 | ||
| 500 | |a Date Revised 04.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Multidrug chemoimmunotherapy with rituximab, high-dose methotrexate, procarbazine and vincristine (R-MPV) is a standard therapy for younger patients with primary central nervous system lymphoma (PCNSL); however, prospective data regarding its use in elderly patients are lacking. This multi-institutional, non-randomised, phase II trial will assess the efficacy and safety of R-MPV and high-dose cytarabine (HD-AraC) for geriatric patients with newly diagnosed PCNSL | ||
| 520 | |a METHODS AND ANALYSIS: Forty-five elderly patients will be included. If R-MPV does not achieve complete response, the patients will undergo reduced-dose, whole-brain radiotherapy comprising 23.4 Gy/13 fractions, followed by local boost radiotherapy comprising 21.6 Gy/12 fractions. After achieving complete response using R-MPV with or without radiotherapy, the patients will undergo two courses of HD-AraC. All patients will undergo baseline geriatric 8 (G8) assessment before HD-AraC and after three, five and seven R-MPV courses. Patients with screening scores of ≥14 points that decrease to <14 points during subsequent treatment, or those with screening scores <14 points that decrease from the baseline during subsequent treatment are considered unfit for R-MPV/HD-AraC. The primary endpoint is overall survival, and the secondary endpoints are progression-free survival, treatment failure-free survival and frequency of adverse events. The results will guide a later phase III trial and provide information about the utility of a geriatric assessment for defining chemotherapy ineligibility | ||
| 520 | |a ETHICS AND DISSEMINATION: This study complies with the latest Declaration of Helsinki. Written informed consent will be obtained. All participants can quit the study without penalty or impact on treatment. The protocol for the study, statistical analysis plan and informed consent form have been approved by the Certified Review Board at Hiroshima University (CRB6180006) (approval number: CRB2018-0011). The study is ongoing within nine tertiary and two secondary hospitals in Japan. The findings of this trial will be disseminated through national and international presentations and peer-reviewed publications | ||
| 520 | |a TRIAL REGISTRATION: jRCTs061180093 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a GERIATRIC MEDICINE | |
| 650 | 4 | |a Lymphoma | |
| 650 | 4 | |a Neurological oncology | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 700 | 1 | |a Fudaba, Hirotaka |e verfasserin |4 aut | |
| 700 | 1 | |a Asano, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sasayama, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Natsumeda, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Shimabukuro, Taichi |e verfasserin |4 aut | |
| 700 | 1 | |a Taguchi, Kotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Nishibuchi, Ikuno |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiyama, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Yonezawa, Ushio |e verfasserin |4 aut | |
| 700 | 1 | |a Yasutomo, Momii |e verfasserin |4 aut | |
| 700 | 1 | |a Kawasaki, Yukari |e verfasserin |4 aut | |
| 700 | 1 | |a Kakuta, Kiyohide |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nagashima, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Tsukamoto, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ideguchi, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Nishizaki, Takafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kurozumi, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hosoya, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Akita, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kambe, Atsushi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 13(2023), 4 vom: 24. Apr., Seite e071350 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:4 |g day:24 |g month:04 |g pages:e071350 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2022-071350 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 4 |b 24 |c 04 |h e071350 | ||